[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363982-105":59,"doc-detail-363982-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","znf689-loss-impairs-homologous-recombination-sensitizing-triple-negative-breast-cancer-to-combined-parp-and-pd-l1-inhibition","ZNF689 loss impairs homologous recombination sensitizing triple-negative breast cancer to combined PARP and PD-L1 inhibition","","Triple-negative breast cancer (TNBC) remains clinically challenging due to aggressive behavior and limited targeted options, especially in BRCA wild-type tumors where PARP inhibitors show restricted benefit. This study identifies zinc-finger protein 689 (ZNF689) as a regulator of homologous recombination (HR) repair, driven by ATM-mediated phosphorylation and downstream MRN complex stabilization. ZNF689 loss increases sensitivity to PARP inhibition, further amplified by paclitaxel, and elevates PD-L1 via STING signaling, improving combined PARP plus anti-PD-L1 efficacy in ZNF689-low TNBC.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/znf689-loss-impairs-homologous-recombination-sensitizing-triple-negative-breast-cancer-to-combined-parp-and-pd-l1-inhibition/363982/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/znf689-loss-impairs-homologous-recombination-sensitizing-triple-negative-breast-cancer-to-combined-parp-and-pd-l1-inhibition/363982.png","ImageObject",300,407,{"name":92,"@type":93},"nayy☆","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does ZNF689 play in homologous recombination (HR) repair in TNBC?","Question",{"text":112,"@type":113},"ZNF689 is recruited to DNA double-strand break sites via ATM-mediated phosphorylation, stabilizing the MRN complex. It also promotes NBS1 ubiquitination through SKP2, leading to ATM activation that facilitates HR repair.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does ZNF689 loss affect sensitivity to PARP inhibitors in TNBC?",{"text":117,"@type":113},"ZNF689 loss markedly enhances TNBC sensitivity to PARP inhibitors, with stronger effects observed especially when PARP inhibition is combined with paclitaxel.",{"name":119,"@type":110,"acceptedAnswer":120},"Why does PARP inhibition increase PD-L1 in ZNF689-deficient TNBC cells?",{"text":121,"@type":113},"PARP inhibition upregulates PD-L1 expression in ZNF689-deficient TNBC cells through activation of the STING pathway.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363982,1790193806,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Article [https://doi.org/10.1038/s41467-026-75031-7](https://doi.org/10.1038/s41467-026-75031-7)  \nZNF689 loss impairs homologous recombination sensitizing triple-negative breast cancer to combined PARP and PD-L1 inhibition  \nReceived: 5 February 2025  \n\n| Accepted: 15 June 2026 |\n| --- |\n| |\n| Check for updates |\n\nLi-Ping Ge1,2,4, Yu-Ling Xiao 1,2,4, Song-Yang Wu 1,2,4, Fang-Lin Zhang1,2, Eo-Ryeong Lee1,2, Gen-Hong Di1,2, Zhi-Ming Shao1,2, Minhong Shen1,2 & Yi-Zhou Jiang 1,2,3   \nTriple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, characterized by a poor prognosis due to the lack of effective targeted therapies. While poly (ADP-ribose) polymerase (PARP) inhibitors beneﬁt BRCA1/2-mutated TNBC, their efﬁcacy in BRCA wild-type tumors remains limited. In this study, we uncover a critical role of zinc-ﬁnger protein 689 (ZNF689) in regulating homologous recombination (HR) repair in TNBC. Our ﬁndings reveal that in response to DNA damage, ZNF689 is phosphorylated by ATM and promotes NBS1 ubiquitination via E3 ligase SKP2, leading to the stabilization of the MRN complex and subsequent ATM activation, thereby facilitating HR repair. ZNF689 loss markedly enhances sensitivity to PARP inhibitors in TNBC, particularly when combined with paclitaxel. Furthermore, PARP inhibition upregulates PD-L1 expression in ZNF689-deﬁcient TNBC cells through activation of the STING pathway. Notably, ZNF689 loss enhances the therapeutic efﬁcacy of PARP inhibition plus anti-PD-L1 immunotherapy. Together, these ﬁndings suggest ZNF689 as a crucial regulator of HR repair and provide proof-of-concept for combining PARP inhibition and PD-L1 blockade in patients with ZNF689-low TNBC.  \nTriple-negative breast cancer (TNBC) is a heterogeneous and highly aggressive subtype of breast cancer, associated with poor overall survival and a high risk of distant recurrence1. Traditional chemotherapy has limited efﬁcacy in TNBC2. A subset of TNBCs is BRCA-mutated and deﬁcient in homologous recombination (HR) repair3. The inhibition of poly (ADP-ribose) polymerase (PARP) in tumors with HR deﬁciency (HRD) has demonstrated synthetic lethality through diverse mechanisms, including the catalytic inhibition of PARP enzymes and the entrapment of PARP-DNA  \ncomplexes4. Consequently, agents such as olaparib and talazoparib have exhibited improved efﬁcacy speciﬁcally in BRCA-mutated breast cancers, when compared to standard chemotherapy5–7. However, these beneﬁts are limited in BRCA wild-type (WT) cancers, which are more prevalent in clinical practice. Therefore, identifying biomarkers for PARP inhibitor (PARPi) response beyond BRCA status, as well as exploring effective combination strategies with PARPi, are crucial for enhancing treatment efﬁcacyin TNBC.  \n1Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Precision Cancer Medicine Center, Fudan University Shanghai Cancer Center, Shanghai, PR China. 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, PR China. 3Shanghai Academy of Natural Sciences (SANS), Fudan University, Shanghai, PR China. 4These authors contributed equally: Li-Ping Ge, Yu-Ling Xiao, Song-Yang Wu.  \ne-mail: [yizhoujiang@fudan.edu.cn](yizhoujiang@fudan.edu.cn)  \nThe generation of DNA double-strand breaks (DSBs) seriously threatens genomic stability and cellular viability. To safeguard the accurate transmission of genetic information, cells activate a DNA damage response (DDR) upon DSB induction. This response entails the activation of kinases such as ATM, ATR, and DNA-PKcs, which subsequently phosphorylate downstream substrates8. These events trigger a downstream cascade that includes cell cycle arrest, post-translational modiﬁcation and transcriptional regulation of repair-related proteins, and recruitment of repair proteins to the sites with damage9,10. Two main strategies have evolved to repair DSBs: non-homologous endjoining (NHEJ) and HR11. NHEJ directly joins broken DNA en","cbCaibdgzLnRQWPb","https://ap.wps.com/l/cbCaibdgzLnRQWPb","pdf",3818145,"English","# Introduction\n## TNBC, PARP inhibitors, and the need for HR biomarkers\n## DNA damage response and DSB repair pathways\n## Zinc-finger proteins and ZNF689 rationale\n# Results\n## ZNF689 loss impairs HR repair activity in TNBC","[{\"question\":\"What role does ZNF689 play in homologous recombination (HR) repair in TNBC?\",\"answer\":\"ZNF689 is recruited to DNA double-strand break sites via ATM-mediated phosphorylation, stabilizing the MRN complex. It also promotes NBS1 ubiquitination through SKP2, leading to ATM activation that facilitates HR repair.\"},{\"question\":\"How does ZNF689 loss affect sensitivity to PARP inhibitors in TNBC?\",\"answer\":\"ZNF689 loss markedly enhances TNBC sensitivity to PARP inhibitors, with stronger effects observed especially when PARP inhibition is combined with paclitaxel.\"},{\"question\":\"Why does PARP inhibition increase PD-L1 in ZNF689-deficient TNBC cells?\",\"answer\":\"PARP inhibition upregulates PD-L1 expression in ZNF689-deficient TNBC cells through activation of the STING pathway.\"}]","ZNF689 loss impairs homologous recombination sensitizing triple-negative breast cancer to combined PARP and PD-L1 inhibition | PDF",1790154761,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/706b5435fb4e10862eeebc6c79974eba.webp",983,1305,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9ce07965e3fdadd3b2ed5bb4c31f96ce.webp",982,1304,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/439bfd4d4983b41547d40728245888e1.webp",981,1303,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2fd9563dbf5d7fb1f4b67b3510b6d953.webp",980,1301]